Andersons pediatric cardiology 1699
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (80.75 KB, 3 trang )
References
1.MillerKD,SiegelRL,LinCC,etal.Cancer
treatmentandsurvivorshipstatistics,2016.CA
CancerJClin.2016;66(4):271–289.
2.WardE,DeSantisC,RobbinsA,KohlerB,
JemalA.Childhoodandadolescentcancer
statistics,2014.CACancerJClin.
2014;64(2):83–103.
3.BloomMW,HamoCE,CardinaleD,etal.
CancerTherapy-relatedcardiacdysfunctionand
heartfailure:part1:definitions,
Pathophysiology,Riskfactors,andimaging.
CirculationHeartfailure.2016;9(1)[e002661].
4.MulrooneyDA,YeazelMW,KawashimaT,et
al.Cardiacoutcomesinacohortofadult
survivorsofchildhoodandadolescentcancer:
retrospectiveanalysisofthechildhoodcancer
survivorstudycohort.BMJ.2009;339:b4606.
5.LipshultzSE,AdamsMJ,ColanSD,etal.Longtermcardiovasculartoxicityinchildren,
adolescents,andyoungadultswhoreceive
cancertherapy:pathophysiology,course,
monitoring,management,prevention,and
researchdirections:ascientificstatementfrom
theAmericanheartassociation.Circulation.
2013;128(17):1927–1995.
6.RinehartJJ,LewisRP,BalcerzakSP.
Adriamycincardiotoxicityinman.AnnIntern
Med.1974;81(4):475–478.
7.BristowMR,MasonJW,BillinghamME,
DanielsJR.Doxorubicincardiomyopathy:
evaluationbyphonocardiography,
endomyocardialbiopsy,andcardiac
catheterization.AnnInternMed.
1978;88(2):168–175.
8.LipshultzSE,CochranTR,FrancoVI,Miller
TL.Treatment-relatedcardiotoxicityinsurvivors
ofchildhoodcancer.NatRevClinOncol.
2013;10(12):697–710.
9.BurridgePW,LiYF,MatsaE,etal.Human
inducedpluripotentstemcell-derived
cardiomyocytesrecapitulatethepredilectionof
breastcancerpatientstodoxorubicin-induced
cardiotoxicity.NatMed.2016;22(5):547–556.
10.MoslehiJ,AmgalanD,KitsisRN.Grounding
Cardio-oncologyinbasicandclinicalscience.
Circulation.2017;136(1):3–5.
11.VejpongsaP,YehET.Preventionof
anthracycline-inducedcardiotoxicity:challenges
andopportunities.JAmCollCardiol.
2014;64(9):938–945.
12.GanameJ,ClausP,UyttebroeckA,etal.
Myocardialdysfunctionlateafterlow-dose
anthracyclinetreatmentinasymptomatic
pediatricpatients.JournaloftheAmerican
SocietyofEchocardiography:official
publicationoftheAmericanSocietyof
Echocardiography.2007;20(12):1351–1358.
13.GanameJ,ClausP,EyskensB,etal.Acute
cardiacfunctionalandmorphologicalchanges
afteranthracyclineinfusionsinchildren.AmJ
Cardiol.2007;99(7):974–977.
14.DarbySC,CutterDJ,BoermaM,etal.
Radiation-relatedheartdisease:current
knowledgeandfutureprospects.IntJRadiat
OncolBiolPhys.2010;76(3):656–665.
15.CarverJR,SzaldaD,KyB.Asymptomatic
cardiactoxicityinlong-termcancersurvivors:
definingthepopulationandrecommendations
forsurveillance.SeminOncol.2013;40(2):229–
238.
16.ZamoranoJL,LancellottiP,RodriguezMunozD,
etal.2016ESCpositionpaperoncancer
treatmentsandcardiovasculartoxicitydeveloped
undertheauspicesoftheESCcommitteefor
practiceguidelines:thetaskforceforcancer
treatmentsandcardiovasculartoxicityofthe
Europeansocietyofcardiology(ESC).Eur
HeartJ.2016;37(36):2768–2801.
